Last edition
News about "US FDA Type A meeting"
Pierre Fabre Pharmaceuticals Reports FDA Update on Tabelecleucel BLA
Pierre Fabre Pharmaceuticals aligns with US Food and Drug Administration (FDA) on BLA resubmission path for tabelecleucel, an allogeneic T-cell therapy for Epstein-Barr virus positive post-transplant lymphoproliferative disease.
US FDA Type A Meeting | 08/05/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members